Table 2. Subgroups analysis of OR and DC achievement in T + P group.
| Characteristics | OR | DC | |||||
|---|---|---|---|---|---|---|---|
| Yes (n=34) | No (n=40) | P value | Yes (n=55) | No (n=19) | P value | ||
| Age, years | 51.3±13.2 | 53.55±11.8 | 0.451 | 53.2±12.2 | 50.6±13.3 | 0.467 | |
| Gender | 0.171 | 1.000 | |||||
| Female | 7 | 3 | 8 | 2 | |||
| Male | 27 | 37 | 47 | 17 | |||
| HBsAg | 0.147 | 0.746 | |||||
| Positive | 25 | 35 | 45 | 15 | |||
| Negative | 9 | 5 | 10 | 4 | |||
| Cirrhosis | 1.000 | 0.643 | |||||
| Yes | 31 | 37 | 51 | 17 | |||
| No | 3 | 3 | 4 | 2 | |||
| Child-Pugh grade | 1.000 | 0.450 | |||||
| A | 33 | 39 | 54 | 18 | |||
| B | 1 | 1 | 1 | 1 | |||
| Portal vein invasion | 0.057 | 0.785 | |||||
| Yes | 17 | 11 | 20 | 8 | |||
| No | 17 | 29 | 35 | 11 | |||
| Hepatic vein invasion | 0.002 | 1.000 | |||||
| Yes | 13 | 3 | 12 | 4 | |||
| No | 21 | 37 | 43 | 15 | |||
| Largest tumor size | 0.061 | 0.429 | |||||
| <5 cm | 13 | 25 | 30 | 8 | |||
| ≥5 cm | 21 | 15 | 25 | 11 | |||
| Tumor number | 0.804 | 0.576 | |||||
| <2 | 12 | 12 | 20 | 5 | |||
| ≥2 | 22 | 28 | 35 | 14 | |||
| ECOG | 0.138 | 0.054 | |||||
| 0–1 | 26 | 23 | 40 | 9 | |||
| 2 | 8 | 17 | 15 | 10 | |||
| BCLC stage | 0.012 | 0.100 | |||||
| A | 3 | 12 | 14 | 1 | |||
| B | 9 | 15 | 15 | 9 | |||
| C | 22 | 13 | 26 | 9 | |||
| AFP | 0.815 | 0.788 | |||||
| <20 ng/mL | 15 | 16 | 24 | 7 | |||
| ≥20 ng/mL | 19 | 24 | 31 | 12 | |||
| WBC, 109/L | 6.5±2.6 | 6.3±2.5 | 0.778 | 6.5±2.7 | 6.2±1.9 | 0.526 | |
| PLT, 109/L | 152.9±85.3 | 172.6±68.7 | 0.283 | 162.4±67.3 | 166.8±101.8 | 0.864 | |
| ALB, g/L | 44.2±4.4 | 45.2±4.5 | 0.300 | 45.2±4.5 | 43.47±4.1 | 0.141 | |
| TBIL, µmol/L | 16.5±7.1 | 15.6±5.1 | 0.541 | 15.6±5.2 | 17.3±8.3 | 0.395 | |
| ALT, U/L | 39.3±20.7 | 41.6±24.5 | 0.670 | 39.9±22.2 | 42.4±24.6 | 0.703 | |
| AST, U/L | 42.6±21.8 | 40.4±23.0 | 0.675 | 41.7±23.6 | 40.7±18.9 | 0.862 | |
OR, objective response; DC, disease control; T + P, tegafur plus pirarubicin; HBsAg, hepatitis B virus surface antigen; ECOG, Eastern Cooperative Oncology Group; BCLC, Barcelona Clinic Liver Cancer; AFP, alpha fetoprotein; WBC, white blood cell; PLT, platelet; ALB, albumin; TBIL, total bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase.